For Pharma Companies

MVI's immunotherapies can help companies define approvable combination regimens for checkpoint inhibitors, market-differentiated regimens with AR axis inhibitors, and position IDO axis inhibitors for success.

MVI is focused on developing the most effective immunotherapies, versus the most potent vaccines.

The MVI approach

  • Developing low cost, stable, simple to dose, immunoactive DNA plasmids offering safe and efficacious combination agents for use with checkpoint inhibitors
  • Clinically focused mindset with our eighth clinical trial underway
  • Therapies across three stages of prostate cancer: non-metastatic, biochemically-recurrent; metastatic, hormone-sensitive; and metastatic, castration-resistant
  • Two plasmid DNA vaccines available targeting PAP and AR
  • Differentiation of specific versions of ADT or AR inhibition in combination with MVI DNA plasmids (provides non-overlapping toxicities, synergistic activity in metastatic disease, ability to keep patients on AR blockade longer by delaying resistance)
  • Combinations and agent sequencing regimens tailored to the specific stage of prostate cancer
  • Strategy aligned with major stakeholders (patients, physicians, regulators, payers, and pharma/biotech)
  • Flexible partnering structures

A strong pipeline of immunotherapies

We offer a singularly strong pipeline, with:

  • 2 vaccines
  • 8 trials
  • 3 different combinations
  • Across 3 stages of disease

Our clinical data is revealing new immunosuppressive metabolic pathway activation, and we have a new combination Tx approach under development.

Clinical trials across all stages

We have clinical trials in progress that are targeting:

  • Non-metastatic, biochemically-recurrent prostate cancer
  • Metastatic, hormone-sensitive prostate cancer
  • Metastatic, castration-resistant prostate cancer

Consistent clinical results

In all trials, we have seen one or more of the following clinical signals:

  • PSA declines including CR and PR
  • Tumor regressions (CT/PET)
  • Delayed TTP

We have a deep clinical biomarker database:

  • CD4/CD8 T-cell responses
  • Checkpoint and Checkpoint ligand responses
  • PSA response
  • TILs/peripheral T-cell phenotypes
  • Quantitative bone imaging data over time
  • Pre-existing and acquired resistance mechanisms
Two business people reviewing something on a tablet